About taysha gene therapies inc - TSHA
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
TSHA At a Glance
Taysha Gene Therapies, Inc.
3000 Pegasus Park Drive
Dallas, Texas 75247
| Phone | 1-214-612-0000 | Revenue | 9.77M | |
| Industry | Biotechnology | Net Income | -108,995,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 17.281% | |
| Fiscal Year-end | 12 / 2026 | Employees | 99 | |
| View SEC Filings |
TSHA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 179.926 |
| Price to Book Ratio | 6.349 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -13.797 |
| Enterprise Value to Sales | 154.377 |
| Total Debt to Enterprise Value | 0.047 |
TSHA Efficiency
| Revenue/Employee | 98,717.172 |
| Income Per Employee | -1,100,959.596 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.026 |
TSHA Liquidity
| Current Ratio | 12.219 |
| Quick Ratio | 12.219 |
| Cash Ratio | 12.06 |
TSHA Profitability
| Gross Margin | 88.284 |
| Operating Margin | -1,130.646 |
| Pretax Margin | -1,115.267 |
| Net Margin | -1,115.267 |
| Return on Assets | -28.678 |
| Return on Equity | -68.451 |
| Return on Total Capital | -34.333 |
| Return on Invested Capital | -48.613 |
TSHA Capital Structure
| Total Debt to Total Equity | 28.559 |
| Total Debt to Total Capital | 22.214 |
| Total Debt to Total Assets | 14.579 |
| Long-Term Debt to Equity | 27.65 |
| Long-Term Debt to Total Capital | 21.508 |